Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Harbour BioMed to Start China Phase III Trial of Autoimmune Therapy

publication date: Sep 3, 2021

Harbour BioMed was approved to start a China Phase II trial of its anti-FcRn (batoclimab) candidate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a chronic disease characterized by progressive weakness and impaired sensory function in the legs and arms. Currently, the condition is treated by corticosteroid pulses and intravenous immunoglobulin (IVIg), but these therapies cause side effects and IVIg is not always available. HBM is headquartered in the Boston area, with discovery operations in Rotterdam and labs in Suzhou. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China